Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. 1993

M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
Vcal, Inc., San Diego, CA 92121.

Direct injection of nonviral, covalently closed circular plasmid DNA into muscle results in expression of the DNA in myofiber cells. We have examined the expression of firefly luciferase DNA constructs injected into adult murine skeletal muscle. Considerable variation in luciferase enzyme expression was noted among constructs with different regulatory elements, among different batches of the same DNA construct, and among similar transfection experiments performed at different times. This variation was minimized by using single batches of plasmid DNA and by performing comparable sets of experiments concurrently. A quantitative experimental protocol was defined for comparing various aspects of the transfection process. We report that a luciferase construct containing the human cytomegalovirus immediate-early gene promoter plus intron A (a construct termed "p-CMVint-lux") showed the highest expression among several constructs tested. Dose-response and time course analyses of p-CMVint-lux DNA injections showed that maximal luciferase expression was achieved with 25 micrograms of DNA at 7-14 days post-injection. Selected manipulations of the transfection process were examined for their influence on luciferase expression. Variations in the rate of DNA injection, needle size, injection volume, and vehicle temperature had no significant effect on luciferase expression. The presence of endotoxin, cationic peptide, muscle stimulants or relaxants, vasoconstrictors, metal chelators, or lysosomal lytic reagents had no significant effect on expression. However, linearization of the DNA, injection of the DNA in water rather than saline, or inclusion of a DNA intercalating agent nearly abolished luciferase expression. And finally, increasing the injection dose by giving multiple injections over a 10-day period increased expression proportionally to the number of injections.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008156 Luciferases Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates. Luciferase
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D005260 Female Females
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
January 1995, Molecular and cell biology of human diseases series,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
January 2004, Journal of biomedical optics,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
November 1994, Plasmid,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
January 2003, Luminescence : the journal of biological and chemical luminescence,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
April 2006, Vaccine,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
February 1999, Proceedings of the National Academy of Sciences of the United States of America,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
January 1991, Chinese journal of biotechnology,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
June 1997, Molecular marine biology and biotechnology,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
August 2003, Acta pharmacologica Sinica,
M Manthorpe, and F Cornefert-Jensen, and J Hartikka, and J Felgner, and A Rundell, and M Margalith, and V Dwarki
February 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!